Edoxaban

Phase 3UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Aortic Valve Stenosis

Conditions

Aortic Valve Stenosis

Trial Timeline

Aug 1, 2019 → Sep 1, 2023

NCT ID

NCT04171726

About Edoxaban

Edoxaban is a phase 3 stage product being developed by Daiichi Sankyo for Aortic Valve Stenosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04171726. Target conditions include Aortic Valve Stenosis.

What happened to similar drugs?

6 of 13 similar drugs in Aortic Valve Stenosis were approved

Approved (6) Terminated (4) Active (5)

❌Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3

✅NOAC + DAPTDaiichi SankyoApproved

🔄Rosuvastatin + PlaceboAstraZenecaPhase 3

🔄candesartan + placeboAstraZenecaPhase 3

✅SugammadexMerckApproved

✅bisoprolol + placeboMerckApproved

✅atorvastatin (Lipitor)PfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05804747	Pre-clinical	Completed	Feb 16, 2023	Jul 28, 2025	Atrial Fibrillation
NCT04747496	Pre-clinical	Completed	Feb 26, 2021	Nov 27, 2024	Non-valvular Atrial Fibrillation
NCT04594915	Pre-clinical	Completed	Aug 14, 2020	Jun 21, 2023	Atrial Fibrillation
NCT04519944	Pre-clinical	Completed	Jun 30, 2020	Jul 6, 2023	Non-valvular Atrial Fibrillation
NCT04171726	Phase 3	UNKNOWN	Aug 1, 2019	Sep 1, 2023	Aortic Valve Stenosis
NCT03840291	Approved	Completed	May 19, 2019	Aug 1, 2024	Atrial Fibrillation
NCT03247569	Pre-clinical	Completed	Oct 18, 2017	Feb 28, 2022	Atrial Fibrillation
NCT03247582	Pre-clinical	Completed	Aug 2, 2017	May 3, 2022	Atrial Fibrillation
NCT02952599	Pre-clinical	Completed	Mar 27, 2017	Oct 29, 2019	Venous Thromboembolism
NCT02951039	Pre-clinical	Completed	Feb 21, 2017	Oct 15, 2020	Atrial Fibrillation
NCT02964949	Pre-clinical	Completed	Jan 24, 2017	Oct 9, 2018	Atrial Fibrillation
NCT02943993	Pre-clinical	Completed	Apr 6, 2016	Dec 1, 2020	Venous Thromboembolism
NCT02944019	Pre-clinical	Completed	Aug 1, 2015	Apr 13, 2022	Atrial Fibrillation
NCT02448901	Pre-clinical	UNKNOWN	Apr 1, 2015	Mar 1, 2016	Heart Failure

Competing Products

20 competing products in Aortic Valve Stenosis

See all competitors

Product	Company	Stage	Hype Score
Apixaban 5 MG + Apixaban 2.5 MG + Warfarin	Artivion	Phase 3	26
NOAC + DAPT	Daiichi Sankyo	Approved	43
Ticagrelor + Placebo	AstraZeneca	Phase 2	35
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
candesartan + placebo	AstraZeneca	Phase 3	36
Sugammadex	Merck	Approved	43
bisoprolol + placebo	Merck	Approved	35
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet	Merck	Phase 2/3	42
Pelacarsen (TQJ230) 80mg + Matching placebo	Novartis	Phase 2	42
fluvastatin	Novartis	Phase 2	31
ACZ885 + Placebo	Novartis	Phase 2	27
Evolocumab + Placebo	Amgen	Phase 1	36
atorvastatin (Lipitor)	Pfizer	Approved	35
Apixaban + Standard of care	Pfizer	Phase 3	40
Ataciguat + Placebo	Sanofi	Phase 1	29
Ataciguat (HMR1766)	Sanofi	Phase 2	35
Haemocomplettan® P + Saline solution	CSL	Phase 2	35
Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)	Bayer	Phase 3	29
Acetylsalicylic acid + Clopidogrel + Rivaroxaban	Bayer	Phase 3	37
Desflurane	Baxter	Approved	36